✦ LIBER ✦

Phase II trial of bisantrene for metastatic melanoma: An illinois cancer council study

✍ Scribed by Stiff, Patrick J. ;Sweet, Donald ;Kilton, Lary J. ;Johnson, Carole M. ;Muntean, Betty ;Blough, Richard R.

Publisher: John Wiley and Sons
Year: 1991
Tongue: English
Weight: 266 KB
Volume: 19
Category: Article
ISSN: 0098-1532
DOI: 10.1002/mpo.2950190211

No coin nor oath required. For personal study only.

✦ Synopsis

Sixteen patients with metastatic melanoma entered this phase II study of the efficacy of monthly cycles of Bisantrene. Toxicity was characterized by leukopenia, resulting in the hospitalization of one patient for a febrile incident, and superficial phlebitis. The results were similar to those of previous studies, in that among the 13 patients evaluable for response (six previously untreated with chemotherapy) there were no responses.

📜 SIMILAR VOLUMES

CCI-779 in metastatic melanoma : A Phase

CCI-779 in metastatic melanoma : A Phase II trial of the California Cancer Consortium

✍ Kim Margolin; Jeffrey Longmate; Tracey Baratta; Tim Synold; Scott Christensen; J 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

A phase II study of CCNU with benznidazo

A phase II study of CCNU with benznidazole for metastatic malignant melanoma

✍ Norman M. Bleehen; J. Trevor Roberts; Hugh F.V. Newman 📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 269 KB

Outpatient combination chemoimmunotherap

Outpatient combination chemoimmunotherapy for patients with metastatic melanoma : Results of a Phase I/II trial

✍ Mohammed Kashani-Sabet; Richard W. Sagebiel; Henry E. Collins; Alan B. Glassberg 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 2 views

## BACKGROUND. Few studies have examined the feasibility, safety, and efficacy of an outpatient biochemotherapy regimen of low dose, subcutaneously administered interleukin-2 (IL-2) for patients with metastatic (Stage IV) melanoma. ## METHODS. Nineteen patients were treated with intravenous cispl

A phase II study of α-difluoromethylorni

A phase II study of α-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma

✍ Frank L. Meyskens; Edwin M. Kingsley; Theodore Glattke; Lois Loescher; Ann Booth 📂 Article 📅 1986 🏛 Springer US 🌐 English ⚖ 414 KB

Difluoromethylornithine (DFMO) is an irreversible enzyme-activated inhibitor of ornithine decarboxylase, a key enzyme in polyamine synthesis. We have screened for potential anti-cancer activity of DFMO using a clonogenic assay, which suggested that melanoma might have sensitivity to this agent. Acco

Phase II study of temozolomide plus pegy

Phase II study of temozolomide plus pegylated interferon-α-2b for metastatic melanoma

✍ Wen-Jen Hwu; Katherine S. Panageas; Jennifer H. Menell; Lynne A. Lamb; Suzan Air 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB

Phase II study of trimetrexate in malign

Phase II study of trimetrexate in malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group Study

✍ Neill A. Iscoe; Elizabeth A. Eisenhauer; Audley J. Bodurtha 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 183 KB

The National Cancer Institute of Canada Clinical Trials Group carried out a phase II trial of trimetrexate given in a daily x 5 intravenous bolus schedule every 3 weeks in patients with measurable metastatic malignant melanoma who had not received previous chemotherapy. Significant hematologic toxic